News | June 18, 2009

Abbott Begins Trial for Next-Generation Xience PRIME DES

June 18, 2009 – Abbott this week initiated SPIRIT PRIME, a clinical trial to study the performance of the company's next-generation Xience PRIME Everolimus-Eluting Coronary Stent System, currently an investigational device, for the treatment of coronary artery disease.

Results from SPIRIT PRIME will be used to support the regulatory filing for Xience PRIME in the U.S. The first patient was enrolled into the SPIRIT PRIME clinical trial at Hillcrest Medical Center in Tulsa, Okla., by Rajesh Chandwaney, M.D.

The company said the Xience PRIME utilizes the same well-studied drug and proven biocompatible polymer as Abbott's market-leading Xience V Everolimus-Eluting Coronary Stent. In addition, it offers a novel stent design and a modified delivery system designed for greater flexibility and improved deliverability, the company said. Xience PRIME uses cobalt chromium technology, which allows for very thin struts, while maintaining strength to support the vessel as well as excellent visibility under X-ray during the stent implantation procedure. The stent is based upon the proven design of the MULTI-LINK family of stents, one of the most widely used stent platforms in the world, with more than 2 million implants. The company expects to launch Xience PRIME in a broad size matrix with sizes up to 38 mm in Europe later this year.

"Xience PRIME carries the same successful drug and polymer as the Xience V stent. Its stent platform and delivery balloon are designed to be highly deliverable, and as such, Xience PRIME has the potential to simplify procedures in challenging cases," said Marco A. Costa, M.D., Ph.D., FACC, FSCAI, professor of medicine, director of the Interventional Cardiology Center, and director of the Center for Research and Innovation, Harrington-McLaughlin Heart and Vascular Institute, University Hospitals Case Medical Center, Case Western Reserve University in Cleveland, Ohio, and principal investigator of the SPIRIT PRIME trial. "Xience V is used routinely in my practice, and I look forward to studying the enhanced features and sizes of Abbott's next-generation drug eluting stent, Xience PRIME."

The SPIRIT PRIME study is a prospective, multicenter, nonrandomized trial designed to study Xience PRIME in 500 patients at 75 hospital centers. Patients may receive a maximum of two stents in separate vessels. SPIRIT PRIME will have two arms: the Core Size arm will follow 400 patients who will be treated with a stent from 2.25 mm to 4 mm in diameter and from 8 mm to 28 mm in length, and the Long Lesion arm will follow 100 patients who will receive a stent from 2.5 mm to 4 mm in diameter and either 33 mm or 38 mm in length. The primary endpoint is major adverse cardiac events (MACE), which is a composite measure of cardiac death, heart attack (myocardial infarction) and repeat procedure of the treated lesion (target lesion revascularization) at one year.

For more information: www.abbott.com, www.xiencev.com

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Registry Identifies Early Onset of Heart Failure and Lack of Defibrillators in Asia
News | Heart Failure| August 03, 2017
August 3, 2017 — The Asian Pacific Society of Cardiology (ASPC) held its first-ever late-breaking...
Overlay Init